Holen Sie sich die Stockscreener-App
3.02
3.07%
0.09
Schlusskurs vom Vortag:
$2.93
Offen:
$2.96
24-Stunden-Volumen:
211.30K
Relative Volume:
0.60
Marktkapitalisierung:
$45.66M
Einnahmen:
$2.09M
Nettoeinkommen (Verlust:
$-30.04M
KGV:
-0.924
EPS:
-3.2685
Netto-Cashflow:
$-27.57M
1W Leistung:
+18.90%
1M Leistung:
+14.39%
6M Leistung:
-27.05%
1J Leistung:
-63.04%
1-Tages-Spanne:
$2.8813
$3.07
1-Wochen-Bereich:
$2.54
$3.07
52-Wochen-Spanne:
$2.13
$10.00
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.02 | 38.40M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-12-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-18 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-07-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
Hopeful Week For Insiders Who Bought US$3.46m Of CervoMed Stock - Simply Wall Street
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
CervoMed Inc. (CRVO) Stock Price, News, Quote & History - Yahoo! Finance Canada
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $12 - Moomoo
FDA Lifts Neflamapimod Dosage Restriction, Boosting CervoMed (CR - GuruFocus
CervoMed (CRVO) Advances Neflamapimod Development with New 50 mg Tablet and FDA Update - GuruFocus
CervoMed advances higher-dose neflamapimod formulation - Investing.com
The new tablet had about 20% lower peaks and about 20% higher levels at 12 hours than the old capsule. - Stock Titan
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference - The Manila Times
A neuroscience panel in New York will include CervoMed management Sept. 29 - Stock Titan
CervoMed (CRVO) Rallies +1.02% as Bulls Target $2.60 2026-09-16Turnaround Stocks - careplusvn.com
CervoMed at Cantor healthcare conference: phase iii path in focus By Investing.com - Investing.com Canada
CervoMed at Cantor healthcare conference: phase iii path in focus - Investing.com India
CRVO: Phase III-ready DLB therapy neflamapimod shows strong efficacy and biomarker support - TradingView
Cervomed Inc (CRVO-Q) Stock Price and News - The Globe and Mail
CervoMed highlights late-breaking neflamapimod Phase 2a data - TipRanks
CervoMed (NASDAQ: CRVO) data accepted for late-breaking dementia conference talk - Stock Titan
CervoMed to present nfvPPA trial biomarker data at ISFTD meeting By Investing.com - Investing.com Nigeria
CervoMed to present neflamapimod trial data at ISFTD - grafa.com
CervoMed to present nfvPPA trial biomarker data at ISFTD meeting - Investing.com
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 - The Manila Times
No approved treatments exist in the U.S. or EU for this dementia type. CervoMed will present trial data. - Stock Titan
CervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB - scanx.trade
CervoMed to Participate in September Investor Conferences - Yahoo! Finance Canada
Price to earnings forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
CRVO News | CERVOMED INC (NASDAQ:CRVO) - ChartMill
CervoMed (CRVO) Edges Lower to $2.62 as Shares Press Against Heavy SupportBPI Reversal - dars.gov.et
CervoMed Company Profile & Introduction - Moomoo
Hedge Fund Armistice Sues Drugmaker, Insiders for Stock Dilution - Bloomberg Law News
CervoMed (CRVO) Results Review: EPS Exceeds Its Estimate in the Latest Session; Price Reaction - dars.gov.et
ARMISTICE CAPITAL, LLC Acquires New Stake in CervoMed Inc (CRVO) - GuruFocus
Roth MKM Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
SABBY MANAGEMENT, LLC's CervoMed Inc(CRVO) Holding History - GuruFocus
CRVO Q2 2026 Earnings: Loss Narrows 27.7% vs Estimates, Shares Dip 6.8%Earnings Cycle Outlook - vinanet.vn
CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares - Stock Titan
CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing - Stock Titan
Woodline Partners (CRVO) discloses 5.1% beneficial stake in CervoMed common stock - Stock Titan
Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund - Stock Titan
CRVO Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.64 Beats Estimates by 27.7%; Shares Slip 4.56% - vinanet.vn
CRVO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $18 - Moomoo
CervoMed at Canaccord Genuity conference: dLB push gains ground By Investing.com - Investing.com Nigeria
CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS - TradingView
CervoMed at Canaccord Genuity conference: dLB push gains ground - Investing.com
CervoMed Inc. (CRVO) Surges 9% as Biotech Stock Approaches Key Resistance at $3.28Stop Loss Guidance - dars.gov.et
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3 - TradingView
CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program - Stock Titan
Canaccord cuts CervoMed stock price target on funding uncertainty By Investing.com - Investing.com India
CervoMed presents data on DLB treatment at AAIC 2026 - scanx.trade
CRVO Maintained by Canaccord Genuity -- Price Target Lowered to $18 - GuruFocus
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cervomed Inc-Aktie (CRVO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Winton Matthew | Chief Commercial and Business |
Nov 17 '25 |
Buy |
8.43 |
3,500 |
29,505 |
13,500 |
| Winton Matthew | Chief Commercial and Business |
Nov 18 '25 |
Buy |
7.95 |
1,500 |
11,925 |
15,000 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
12,500 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
1,484,078 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 18 '25 |
Buy |
8.32 |
2,500 |
20,800 |
12,500 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 17 '25 |
Buy |
8.45 |
1,000 |
8,450 |
10,000 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
1,484,078 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
12,500 |
| Gregoire Sylvie | Director |
Nov 13 '25 |
Buy |
7.51 |
4,447 |
33,397 |
1,471,578 |
| Gregoire Sylvie | Director |
Nov 14 '25 |
Buy |
7.57 |
1,707 |
12,922 |
1,473,285 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):